Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799370 | 0.83 | POLB (0.42) | POLBHSD11B1L3MBTL1MEN1KMT2A | |
| SCHEMBL9962271 | 0.79 | ALDH1A1 (0.51) | POLBHSD11B1L3MBTL1 | |
| SCHEMBL15829877 | 0.78 | HTR2A (0.44) | POLBHSD17B10HSD11B1L3MBTL1MEN1 | |
| SCHEMBL19287839 | 0.78 | SIGMAR1 (0.54) | L3MBTL1 | |
| SCHEMBL18331595 | 0.77 | CTSB (0.42) | HSD17B10HSD11B1MEN1KMT2A | |
| SCHEMBL3925077 | 0.75 | POLB (0.43) | POLBHSD11B1L3MBTL1 | |
| SCHEMBL16885697 | 0.75 | ALDH1A1 (0.42) | HSD17B10HSD11B1MEN1KMT2A | |
| SCHEMBL15473886 | 0.74 | HTR6 (0.47) | POLB | |
| SCHEMBL31344705 | 0.74 | HSD11B1 (0.44) | POLBHSD11B1L3MBTL1 | |
| SCHEMBL19287742 | 0.74 | SLC6A2 (0.39) | POLBHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343826-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | POLB 2703/4885ELANE 4249/4885HSD17B10 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.